Association between serum sirt 1 and advanced glycation end products levels in type 2 diabetic nephropathy patients
Paper Details
Association between serum sirt 1 and advanced glycation end products levels in type 2 diabetic nephropathy patients
Abstract
This study aimed to evaluate the association between serum sirtuin1 (Sirt1) and AGEs levels in type 2 diabetes patients with different stages of diabetic kidney disease. Eighty type 2 diabetes patients were divided into three groups: normoalbuminuric group, microalbuminuric group, and macroalbuminuric group, along with 20 age and sex-matched healthy individuals were included in the study. Fasting blood glucose, fasting insulin, Homeostasis model assessment for insulin resistance (HOMA-IR), renal function tests, lipid profile, serum Sirt1 (ELISA) and serum AGEs (ELISA) were evaluated. Comparing to the control group, serum Sirt1 level was significantly lowered in normoalbuminric patients (p< 0.05). While, serum level of AGEs was significantly increased in all diabetic patients (p< 0.001). Serum Sirt1 was negatively correlated with microalbumin in macroalbuminuric patients. Additionally, serum Sirt1 showed a positive correlation with insulin and AGEs levels in total diabetic patients (p< 0.05 and p< 0.001 respectively). Multiple linear regression analysis showed that serum AGEs level was the only independent factor for Sirt1 in diabetic groups. In conclusion: Serum Sirt1 may be associated with minimal renal impairment in type 2 diabetic nephropathy patients.
Afkarian M, Sachs MC, Kestenbaum B. 2013. Kidney disease and increased mortality risk in type 2 diabetes. Journal of the American Society of Nephrology 24, 302 –308.
Baynes JW, Thorpe SR. 1999. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48, 1–9.
Bordone L, Motta MC, Picard F. 2006. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biology 4e, 31.
Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. 2012. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and Sirtuin 1. Proceedings of the National Academy of Sciences 109, 15888–15893.
Chuang PY, Dai Y, Liu R, He H, Kretzler M, Jim B. 2011. Alteration of forkhead boxO (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 6 e, 235-66.
Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. 2015. Inflammatory Cytokines in Diabetic Nephropathy. Journal of diabetes research 2015, 948417.
Guarente L, Franklin H, Epstein L. 2011. Sirtuins, aging, and medicine. New England journal of medicine 364, 2235-44.
Haigis MC, Guarente LP. 2006. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes & development 20, 2913-2921.
Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K , Koya D. 2011. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of sirt1 in diabetic wistar fatty (fa/fa) rats: a model of type 2 diabetes. Expermental Diabetes Research 2011, 908185.
Kumar R, Sharma RK, Agarwal S. 2013. Genetic predisposition for development of nephropathy in type 2 diabetes mellitus. Biochemical genetics 51, 865-75.
Kume S, Uzu T, Horiike K, Chin-Kanasaki M, Isshiki K, Araki S, Sugimoto T, Haneda M, Kashiwagi A, Koya D. 2010. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. journal of clinical investigation 120, 1043–1055.
Lee JH, Song MY, Song EK, Kim EK, Moon WS, Han MK, Park JW, Kwon KB, Park BH. 2009. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappa B signaling pathway. Diabetes 58, 344-51.
Makino A, Scott BT, Dillmann WH. 2010. Mitochondrial fragmentation and superoxide anion production in coronary endothelial cells from a mouse model of type 1 diabetes. Diabetologia 53, 1783–1794.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412– 419.
Monnier VM, Sell DR, Genuth S. 2005. Glycation products as markers and predictors of the progression of diabetic complications. Annals of the New York Academy of Sciences 1043, 567–581.
Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Méneur C, Permutt MA, Imai S. 2005. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metabolism 2, 105-117.
Nakagawa T, Tanabe K, Croker BP, Johnson RJ, Grant MB, Kosugi T, Li Q. 2011. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nature reviews. Nephrology 7, 36–44.
Shao Y, Ren H, Lv C, MaX, Wu C, Wang Q. 2017. Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease. Endocrine 55, 130-138.
Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. 2000. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 49, 1030 -5.
Verzola1 D, Gandolfo MT, Ferrario F, Rastaldi MP, Villaggio B, Gianiorio F, Giannoni M, Rimoldi L, Lauria F, Miji M , Deferrari G, Garibotto G. 2007. Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney International 72, 1262–1272.
Wang XL, Wu LY, Zhao L, Sun LN, Liu HY, Liu G, Guan GJ. 2016. SIRT1 activator ameliorates the renal tubular injury induced by hyperglycemia in vivo and in vitro via inhibiting apoptosis. Biomedicine & pharmacotherapy 83, 41-50.
Wu J, Zhang R, Torreggiani M, Ting A, Xiong H, Striker GE, Vlassara H, Zheng F. 2010. Induction of diabetes in aged C57B6 mice results in severe nephropathy: an association with oxidative stress, endoplasmic reticulum stress, and inflammation. The American journal of pathology 176, 2163–76.
Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE. 2015. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clinical journal of the American Society Nephrolgy 10, 759–66.
Shadia A. Fathy, Doaa M. Ibrahim, Wafik A. Elkhayat, Haidi S. Ahmed, 2017. Association between serum sirt 1 and advanced glycation end products levels in type 2 diabetic nephropathy patients. Int. J. Biosci., 10(5), 398-404.
Copyright © 2017 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.